Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TB Treatment)

Next Previous
Search
Trial Profile

Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TB Treatment)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bedaquiline (Primary) ; Delamanid (Primary) ; Moxifloxacin (Primary) ; Pyrazinamide (Primary) ; Pyridoxine (Primary) ; Rifabutin (Primary)
  • Indications Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Acronyms CRUSH-TB

    • Most Recent Events

    • 11 Feb 2025 Planned End Date changed from 31 Dec 2026 to 31 Dec 2027.
    • 11 Feb 2025 Planned primary completion date changed from 30 Oct 2025 to 31 Dec 2026.
    • 05 Jan 2024 Planned End Date changed from 30 Apr 2026 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top